BTIG reiterated its buy recommendation and $55 price target for Medline Inc. (NASDAQ: MDLN) following a facility tour in Grayslake, Illinois, co-organized by analyst David Larsen.
The stock last traded at $34.58, up 6% from its 52-week low of $32.48 and down 27% over the past six months. BTIG’s price target implies roughly 59% upside from current levels. Medline reported second-quarter 2026 revenue of $7.7 billion, a 12% year-over-year increase, and adjusted earnings of $0.50 per share.
The tour included a visit to Medline’s 1.5 million square-foot medical-grade distribution center in Grayslake, one of the company’s 45 U.S. facilities. Analysts and investors met with Medline management and participated in a Q&A with the facility manager. The company also highlighted its supply chain operations during the event.
Medline’s shares have faced pressure after missing EBITDA consensus in the first quarter of 2026 and lowering full-year 2026 EBITDA guidance in the second quarter. According to InvestingPro, 19 analysts have revised their earnings estimates downward for the upcoming period. Tigress Financial Partners adjusted its price target from $62 to $55 while maintaining a buy rating, citing Medline’s AI-enabled supply chain transformation and recent operational challenges as factors supporting long-term value.
